The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the market. A shift away from Schedule I status, often viewed as outdated and hindering https://marvinvprh714459.wikiadvocate.com/17617/pot_rescheduling_a_growth_catalyst